MARX Biotech Joins Forces with Livestream Superstar “Diudiu33”！
MARX Biotech (7731 TT), a leading player in the health retail sector, has announced a strategic alliance with renowned livestreaming influencer Sammi Li, also known by her stage name "Diudiu 33" , as part of its ongoing efforts to expand its livestreaming business. This collaboration aims to leverage livestreaming to expand MARX Biotech's market presence and to develop the fifth new brand under the MARX umbrella.
The signing ceremony took place yesterday (30th), marking a significant step in MARX Biotech's ambition to dominate both domestic and Southeast Asian markets. Diudiu33 will help promote Mars Biotech's products through her extensive online presence, bringing her expertise and following to the company. This partnership will focus on integrating online and offline channels, brand diversification, segmented market strategies, and combining their strengths to enhance competitiveness in the global health retail market.
"Strengthening Market Position through OMO Integration"
MARX Biotech's innovative Online Merge Offline (OMO) strategy underpins its retail platform, encompassing a robust B2B system that manages over 3,400 physical pharmacy and drugstore channels. This system not only aids pharmacies in boosting their profitability but also scales market reach. This year, MARX Biotech has intensified its focus on livestreaming with the launch of its sales website, aiming to broaden its influence beyond official websites and domestic and international e-commerce platforms by engaging directly with social media audiences.
※Sales website：
https://MARXlive.shoplineapp.com/
"Livestream Diva Set to Drive Another Wave of Growth"
Diudiu 33, who has a remarkable sales record of NT$200 million in a single month, brings her extensive network of over 1.55 million followers across two major livestreaming platforms to the partnership. She is set to promote MARX Biotech's products and her own newly developed brand, which will become MARX Biotech's fifth brand, through regular livestreams. This new venture targets untapped markets, leveraging Diudiu's popularity to drive significant sales growth.
MARX Biotech has already reported a threefold increase in revenue in the first four months of the year, even during a typically slow season. With upcoming peak shopping events such as the 618 Shopping Festival, Father's Day, Double 11, Double 12, and anniversary sales, the addition of Diudiu's livestreaming influence is expected to further accelerate revenue growth, surpassing the gains achieved in the early part of the year.
"Diverse Brand and Market Expansion Spurs Rapid Revenue Increase"
Currently, MARX Biotech manages four distinct brands—TAIZAKU, Phargoods+, inyouso, and SnowIOU—each designed to meet the varied needs of different consumer segments. By leveraging its comprehensive online and offline distribution channels, MARX Biotech continues to stand out in the competitive health products market. In 2023, the company achieved a 162.04% increase in revenue, reaching NT$290 million. For the first four months of this year, revenue surged by 314.01% compared to the same period in 2023, already accounting for 50% of last year's total revenue. Each brand is expected to release 1-2 new products annually, ensuring continued growth and engagement with existing audiences.
"A Clear Roadmap for Expansive Growth"
MARX Biotech remains committed to expanding both its domestic and international brand portfolio and distribution channels. The mid-term goal is to capture 20% of pharmacy health product sales. With over 2,000 health product items available in an average pharmacy, MARX Biotech's current offering of more than 120 products indicates significant potential for market share growth. The company plans to replicate the successful business models of Phargoods+ and SnowIOU by integrating and acquiring small to mid-sized health brands across Taiwan and other regions, targeting the addition of 3-10 new brands annually. This strategy aims to create a comprehensive product line, supported by its exclusive B2B system (PharBuy), fulfilling pharmacy procurement needs and solidifying MARX Biotech's position as a leader in the health sector.
The signing ceremony took place yesterday (30th), marking a significant step in MARX Biotech's ambition to dominate both domestic and Southeast Asian markets. Diudiu33 will help promote Mars Biotech's products through her extensive online presence, bringing her expertise and following to the company. This partnership will focus on integrating online and offline channels, brand diversification, segmented market strategies, and combining their strengths to enhance competitiveness in the global health retail market.
"Strengthening Market Position through OMO Integration"
MARX Biotech's innovative Online Merge Offline (OMO) strategy underpins its retail platform, encompassing a robust B2B system that manages over 3,400 physical pharmacy and drugstore channels. This system not only aids pharmacies in boosting their profitability but also scales market reach. This year, MARX Biotech has intensified its focus on livestreaming with the launch of its sales website, aiming to broaden its influence beyond official websites and domestic and international e-commerce platforms by engaging directly with social media audiences.
※Sales website：
https://MARXlive.shoplineapp.com/
"Livestream Diva Set to Drive Another Wave of Growth"
Diudiu 33, who has a remarkable sales record of NT$200 million in a single month, brings her extensive network of over 1.55 million followers across two major livestreaming platforms to the partnership. She is set to promote MARX Biotech's products and her own newly developed brand, which will become MARX Biotech's fifth brand, through regular livestreams. This new venture targets untapped markets, leveraging Diudiu's popularity to drive significant sales growth.
MARX Biotech has already reported a threefold increase in revenue in the first four months of the year, even during a typically slow season. With upcoming peak shopping events such as the 618 Shopping Festival, Father's Day, Double 11, Double 12, and anniversary sales, the addition of Diudiu's livestreaming influence is expected to further accelerate revenue growth, surpassing the gains achieved in the early part of the year.
"Diverse Brand and Market Expansion Spurs Rapid Revenue Increase"
Currently, MARX Biotech manages four distinct brands—TAIZAKU, Phargoods+, inyouso, and SnowIOU—each designed to meet the varied needs of different consumer segments. By leveraging its comprehensive online and offline distribution channels, MARX Biotech continues to stand out in the competitive health products market. In 2023, the company achieved a 162.04% increase in revenue, reaching NT$290 million. For the first four months of this year, revenue surged by 314.01% compared to the same period in 2023, already accounting for 50% of last year's total revenue. Each brand is expected to release 1-2 new products annually, ensuring continued growth and engagement with existing audiences.
"A Clear Roadmap for Expansive Growth"
MARX Biotech remains committed to expanding both its domestic and international brand portfolio and distribution channels. The mid-term goal is to capture 20% of pharmacy health product sales. With over 2,000 health product items available in an average pharmacy, MARX Biotech's current offering of more than 120 products indicates significant potential for market share growth. The company plans to replicate the successful business models of Phargoods+ and SnowIOU by integrating and acquiring small to mid-sized health brands across Taiwan and other regions, targeting the addition of 3-10 new brands annually. This strategy aims to create a comprehensive product line, supported by its exclusive B2B system (PharBuy), fulfilling pharmacy procurement needs and solidifying MARX Biotech's position as a leader in the health sector.